Status:
UNKNOWN
Efficacy and Safety of Camrelizumab in Real-World Prospective Study
Lead Sponsor:
Guangdong Association of Clinical Trials
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.
Detailed Description
Camrelizumab is a humanized antibody for cancer immunotherapy. The National Medical Products Administration (NMPA, China) approved camrelizumab as a first-line treatment of certain patients with NSCLC...
Eligibility Criteria
Inclusion
- Sign the informed consent and volunteer to participate in the study;
- Non-small cell lung cancer confirmed by histological/cytopathological tests;
- Age ≥18;
- The investigators determined that patients should receive camrelizumab alone or in combination.
Exclusion
- Patients who are also receiving other immunomedications or therapies;
- Patients participating in other interventional studies;
- Patients complicated with other malignant tumors;
- Women who have been confirmed to be pregnant or lactating;
- The Investigator considers the patient unsuitable for participation in any other condition of the study.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04793139
Start Date
April 1 2021
End Date
December 30 2024
Last Update
March 11 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.